Neo Ivy Capital Management Raises Holdings in Johnson & Johnson $JNJ

Neo Ivy Capital Management boosted its stake in Johnson & Johnson (NYSE:JNJ) by 29.9% during the second quarter, Holdings Channel.com reports. The firm owned 10,964 shares of the company’s stock after buying an additional 2,522 shares during the period. Neo Ivy Capital Management’s holdings in Johnson & Johnson were worth $1,675,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. YANKCOM Partnership grew its holdings in Johnson & Johnson by 0.8% in the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock worth $1,076,000 after acquiring an additional 58 shares during the last quarter. DNB Asset Management AS boosted its holdings in shares of Johnson & Johnson by 4.0% during the second quarter. DNB Asset Management AS now owns 1,256,126 shares of the company’s stock worth $191,873,000 after purchasing an additional 47,950 shares during the period. Swiss National Bank grew its stake in shares of Johnson & Johnson by 7.4% in the second quarter. Swiss National Bank now owns 7,294,807 shares of the company’s stock worth $1,114,282,000 after purchasing an additional 504,100 shares during the last quarter. Willis Investment Counsel increased its holdings in Johnson & Johnson by 8.4% during the 2nd quarter. Willis Investment Counsel now owns 360,134 shares of the company’s stock valued at $55,010,000 after purchasing an additional 28,043 shares during the period. Finally, ABN AMRO Bank N.V. purchased a new stake in Johnson & Johnson in the 2nd quarter worth approximately $369,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $203.29 on Friday. The company’s fifty day moving average price is $187.74 and its 200-day moving average price is $171.22. The stock has a market cap of $489.77 billion, a PE ratio of 19.62, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $204.51.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research analyst reports. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research report on Monday, October 6th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a research report on Friday, October 10th. Finally, Argus set a $210.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.